The physiological interrelationships between cognitive impairments, neurotransmitter loss, amyloid processing and energy metabolism changes in AD, cholinergic dementia and Down's syndrome are largely unknown to date. This report contains novel studies into the association between cognitive function and cerebral metabolism after long-term selective CNS cholinergic neuronal and synaptic loss in a rodent model. We measured local cerebral rates of glucose utilization ( 
INTRODUCTION
Alzheimer's disease (AD) is a complex neurological disorder typified by a progressive cognitive decline. The disease is neurochemically and pathologically characterized by APP mismetabolism, extracellular deposition of amyloid ␤-peptide (A␤)-containing neuritic plaques and intraneuronal tau-containing fibrillary tangles. There is also extensive synaptic and neuronal loss in allo-and neocortex, along with a marked degeneration and loss of cholinergic neurons within the basal forebrain (BF), and reduced choline acetyl transferase (ChAT) in cortex and hippocampus (7, 8, 10, 14, 66, 79) . Another common finding in affected individuals is reduced glucose metabolism in cortical and hippocampal regions, detected by positron emission tomography (PET), notable as these are the primary projection targets of BF cholinergic efferents (19, 22, 23) .
The definitive roles and interactions of cognitive, cholinergic, energy dysfunction and amyloid deposition in the pathogenesis of AD are still unclear (4, 5, 28, 81) . Experimental studies, both in vitro and in vivo, indicate that cholinergic function may regulate A␤ formation by modulating APP processing (45, 56) . APP cleavage at either the N-or C-terminus of the A␤ domain (by ␤-or ␥-secretase, respectively) generates A␤ which can aggregate to form amyloid plaques. In contrast, cleavage within the A␤ domain by ␣-secretase results in secretion of soluble peptide (APPs) into the extracellular space, which has been postulated to have neuroprotective or neurotrophic effects (50) . In vitro and in vivo (45, 53, 58) preclinical studies showed that activation of muscarinic acetylcholine (ACh) receptors, primarily muscarinic ACh M1, can accelerate ␣-secretase processing of APP, potentially reducing neuronal content and extracellular release of putatively harmful A␤ peptides. This reduction of A␤ levels has also recently been demonstrated after M1 agonist treatment in AD patients (57) . Removal of the basal forebrain cholinergic innervation of cortex and hippocampus permanently increases APP expression in deafferented regions and reduces APP secretion into extracellular space (40, 45, 46, 70) . The specificity of the cholinergic system for APP regulation within the forebrain is supported by findings that cortical dopaminergic denervation by 6-OHDA lesions in rats had no effect on APP levels (46) .
Previous functional studies of the BF cholinergic system have been hampered by the lack of a selective cholinergic neurotoxin (9, 47, 60) . In this study we used a monoclonal antibody to the low affinity nerve growth factor (NGF) receptor, 192 IgG, coupled to a ribosomeinactivating cytotoxin, saporin, to lesion the cholinergic BF projection, and examined the functional affects on glucose metabolism and cognition. NGF provides trophic support to cholinergic BF neurons that express high levels of the low affinity NGF receptor p75NGFR in the adult rat brain. Intracerebroventricular (i.c.v.) injection of 192 IgG-saporin selectively destroys p75NGFR-bearing cells, which include principally cholinergic BF neurons and, to a much lesser extent, cerebellar purkinje cells. Therefore, intraventricular injection of 192 IgG-saporin produces an almost complete lesion of cortical and hippocampal cholinergic afferents arising from the BF, while sparing other neuronal populations within the BF and other brain regions (29, 71) . We measured local cerebral glucose use by [ 14 C]-2-deoxyglucose autoradiography in conscious rats 4.5 months after lesioning the basal forebrain cholinergic system via i.c.v. injections of 192 IgG-saporin. Cholinergic denervation was verified by assessment of [ 3 H]-vesamicol binding to localize the presynaptic vesicular acetylcholine transporter. Four days prior to the 2-deoxyglucose procedure, animals underwent behavioral testing in a Morris water maze.
MATERIALS AND METHODS

Animals.
Sixteen female, adult Sprague-Dawley rats (200 -230 g preoperative weights) were used in the experiments (Charles River Laboratories, MA). Rats were held in a controlled temperature environment under a 12-h light/dark cycle, and allowed free access to food and water for the duration of the experimental period. The two groups were 192 IgG-saporin lesioned (n ϭ 8) and aged-matched controls (n ϭ 8) housed in parallel.
Cholinergic lesion surgery. Rats were anaesthetized using ketaset/xylazine (67/6.7 mg/kg i.m., Sigma, St. Louis, MO) and placed in a stereotactic frame (David Kopf, Tujunga, CA). Bilateral i.c.v. injections were made at the following stereotaxic coordinates: AP Ϫ0.6 mm (from bregma); L Ϯ 1.5 mm (lateral to midline); V Ϫ3.5 mm (below dura); incisor bar set Ϫ3.4 mm (45, 64) . 192 IgG-saporin (total 5 g, 1 g/l, 2.5 l/side; 1 /min; Chemicon International, Temecula, CA) was injected via a 10 l Hamilton syringe connected to a 26-gauge needle with a 45°beveled tip. Needles were left in place for 3-min before removal. Animals received daily injections of sterile saline (0.9%; 5 ml s.c.) for 1 week postsurgery to minimize dehydration. All rats appeared normal with no weight loss by two weeks postsurgery.
Behavioral analysis. Eighteen weeks postsurgery, rats received behavioral tests to assess parameters of cognitive performance in a Morris water maze task, as previously described (43, 46) (Poly-Track Video Tracking System, San Diego Instruments, San Diego, CA). Briefly, a circular six-foot tank was filled with water at room temperature and a clear plexiglass platform was submerged one inch underwater in the southwest quadrant of the pool. On the day immediately preceding the test, animals received two 1-min trials in the tank without the platform present to allow for habituation to the maze. Starting on Day 1, the rats were given six trials per day for five consecutive days, each trial lasting a maximum of 60 s or until the rat escaped to the platform. If the rats failed to find the platform, the experimenter placed them there. A 15-s rest period on the platform followed each trial. In each trial the rats were randomly placed in the tank from four fixed points (designated North, South, East and West). On the last day of testing the rats received a "spatial probe trial," where the platform was removed from the tank and the rats were allowed to swim for 60 s. Total swim time (escape latency), distance to the platform and swim speed as well as time spent in the target quadrant were recorded for each rat for each trial. Glucose use values were measured bilaterally in 24 discrete CNS regions. Regions of interest were chosen to reflect cholinergic nuclei, cholinergic projection targets, and control regions lacking major direct cholinergic innervation. Presynaptic vesicular ACh transporter densities were determined in the same 22 regions in 20-m-thick brain sections adjacent to the sections used for glucose use measurements. Densitometric data in each brain region examined were compared between lesioned and nonlesioned animals using an unpaired Student's t test. Correlational analysis with corrections for multiple comparisons were performed on specific glucose utilization values and behavioral performance (JMP program, Version 3.1.6, SAS Institute). Differences were considered statistically significant when P Ͻ 0.05.
RESULTS
Behavioral Tests
Rats showed behavioral deficits in the Morris water maze test 18 weeks after bilateral i.c.v. injections of 192 IgG-saporin, similar to those previously described (40, 43, 46) . Lesioned animals generally exhibited significantly longer escape latencies. On the final day of testing, the performance of non-lesioned animals was 24 Ϯ 3 s vs 9 Ϯ 2 s of lesioned rats (P Ͻ 0.001). In the spatial probe task trial on day 1, 2, and 5, lesioned animals spent significantly less time in the target quadrant than non-lesioned controls (day 5: 39 Ϯ 3% vs 58 Ϯ 3%, lesioned vs control rats, P Ͻ 0.001). Swim speed was slightly higher in the lesioned animals on day 1, 2, 3, and 5 of testing (day 5 ϭ 8.69 Ϯ 0.43 vs 7.29 Ϯ 0.23, lesioned vs control rats, P Ͻ 0.05).
On the day of the [ 14 C]-2-DG procedure the partially restrained, conscious rats were lively and alert, and exhibited normal grooming and sniffing behavior throughout the experimental period. Physiological variables measured 5 min before commencement of the [ 14 C]-2-DG procedure are presented in Table 1 . None of the measured parameters (pCO 2 , pO 2 , pH, arterial plasma glucose concentration and rectal temperature) differed significantly between lesioned and control animals. Measured pO 2 levels in both control and lesioned rats were slightly below normal physiological levels, but all other parameters were within normal physiological limits.
(ii) Local cerebral glucose utilization. The effects of 192 IgG-saporin i.c.v. injections on cerebral glucose use 18 weeks post-lesion are presented in Table 2 . Statistically significant (P Ͻ 0.05) reductions in glucose use were evident in four brain regions after cholinergic deafferentation, while trends toward reduced glucose use were evident in several other regions including 14 C]-2-deoxyglucose procedure in 192 IgG-saporin-lesioned (n ϭ 6) and nonlesioned (control, n ϭ 6) rats. There were no statistically significant differences between saporinlesioned and nonlesioned (control) animals in any of the parameters measured (P Ͼ 0.05, Student's unpaired t test). most notably primary projection targets for NBM/septum cholinergic efferents.
Basal forebrain (BF) cholinergic projection sites. Glucose utilization was significantly reduced in the hippocampus CA1 and CA3 subfields (Ϫ32 and Ϫ29%, respectively), in the dentate gyrus molecular layer (Ϫ22%; Fig. 1 ) and in the deep layers of parietal cortex (Ϫ21%). In addition, trends toward glucose use reductions (Ϫ14 -21%) were evident in other primary cholinergic projection targets of basal forebrain nuclei, including prefrontal, frontal and parietal cortices, and the amygdaloid nucleus.
Basal forebrain regions. Glucose utilization values did not significantly differ between lesioned and nonlesioned animals in any of the eight basal forebrain regions examined containing cholinergic neuron cell bodies, although trends toward reduced metabolism were evident in the nucleus basalis magnocellularis (NBM), diagonal band of Broca (DBB), and striatal subregions.
Secondary BF projection sites and other areas. Glucose use values were unaltered in globus pallidus, substantia nigra pars compacta and reticulata, and cerebellar regions. 3 H]-Vesamicol binding densities were markedly reduced in the hippocampus CA1 and CA3 subfields (Ϫ71 and Ϫ65%, respectively), and in the dentate gyrus molecular layer (Ϫ72%) 18 weeks after 192 IgG-saporin lesions, relative to levels in non-lesioned, control animals (P Ͻ 0.05). In addition, marked trends towards reduced [ 3 H]-vesamicol binding were also evident in pre-frontal cortex sublayers (Ϫ50 -63%) as demonstrated in Fig. 1 , and to a lesser extent in parietal and frontal cortices, although these did not reach statistical significance with the group sizes employed.
Basal forebrain region. [ 3 H]-Vesamicol binding was significantly decreased in the ventromedial striatum 18 weeks postlesion (Ϫ60%, P Ͻ 0.05; Fig. 1 ), and showed a trend toward reduction in the nucleus accumbens (Ϫ31%).
Secondary BF projection sites and other areas. 
Correlation Analyses: Behavioral Deficits and Cerebral Glucose Metabolism
Although both escape latency and distance swum are usually good indicators of spatial performance impairment in rats with cholinergic deficits, it is possible that swim speed may affect escape latency in the water maze. Therefore, we chose to correlate the spatial probe task performance (percentage of time spent in target-quadrant) measured in individual animals, with their respective local rates of glucose utilization in the 24 different brain regions examined. Results for this Note. Data are mean Ϯ SEM local cerebral rates of glucose utilization (mol/100 g/min) 18 weeks after bilateral i.c.v. injection of 192 IgG-saporin (saporin-lesioned), and in control (nonlesioned) animals (n ϭ 6 per group). Roman numerals indicate layers of cerebral cortex. *P Ͻ 0.05, significantly reduced glucose utilization relative to control values (Student's unpaired t test). measure of cognitive performance compared to glucose utilization are presented for nonlesioned, control rats and 192 IgG-saporin i.c.v.-injected rats in Table 4 .
There was no evidence of a significant dependence between performance in the spatial probe task trial and glucose use in any single region of the 24 brain areas examined in control rats (Table 4) . However, in lesioned rats, the degree of correlation with glucose utilization and performance markedly increased in many brain regions, reaching statistical significance in frontal cortex layers IV, V, and VI, DBB, rostral septum, dorsomedial striatum, and the substantia nigra (Table 4) .
DISCUSSION
The aim of this study was to gain insight into the inter-dependencies existing between cholinergic deafferentation, cognitive dysfunction and cerebral metabolic impairment in a rodent model. We investigated cholinergic loss, cognitive performance in a mazelearning task, and cerebral metabolism in rats with basal forebrain (BF) cholinergic deficits produced by prior i.c.v. injections of 192-IgG saporin. We have previously shown that cholinergic denervation alters APP processing in the neocortex and hippocampus, which can be modified by muscarinic M1 receptor agonist activation (45, 46) . In summary, our results show that a selective depletion of BF cholinerigic neurons results in sustained impairment of glucose utilization in cholinoceptive regions, which is correlated with spatial learning deficits. These findings provide firstly, novel evidence of the long-term selective hypometabolic sequelae of cholinergic denervation, in addition to insights into possible links between cholinergic degener- . Note that glucose utilization is reduced in the dentate gyrus molecular layer (DG, arrow) of the IgG-saporin-lesioned animal (C) relative to levels in the non-lesioned animal (A). Decreased glucose utilization is also evident in medial cortical regions, but is relatively unaltered in other brain areas. In B and D, 3 H-vesamicol binding is markedly reduced in the prefrontal cortex (PreFCX, arrow) following IgG-saporin injections (D, arrowhead), despite sustained binding levels in the striatum, consistent with loss of cholinergic terminals in the cortex. Findings suggest that i.c.v. IgG-saporin injection damages cholinergic neurons, including basal-forebrain-cortex efferents, and results in chronic depression of functional activity in polysynaptic projection targets of this pathway. ation, energy metabolic dysfunction and cognitive impairment in AD.
Cholinergic Lesions of the Basal Forebrain by 192
IgG-Saporin Efferent projections from the nucleus basalis magnocellularis (NBM) region of the BF provide the major extrinsic cholinergic innervation of the neocortex and modulate functional activities including learning, memory and attention, as well as physiological parameters such as cerebral blood flow in the cortex. The NBM also projects to the amygdala (1, 18, 67) , while the diagonal band of Broca (DBB) and the medial septum (MS) innervate the hippocampus (16, 65) . In the present study, i.c.v. administration of 192 IgG-saporin in rats reduced cholinergic innervation in regions targeted by BF cholinergic projection, notably the prefrontal cortex, hippocampus CA1, CA3, and dentate gyrus, as reflected by lower [ 3 H]-vesamicol binding to presynaptic vesicular ACh transport sites in these regions. Taken with our previous findings of cholinergic neuronal loss in the NBM (with sparing in other regions) and reduced ChAT activity in the hippocampus and cortex following the same 192 IgG-saporin injection paradigm (46) , these findings provide further evidence that 192 IgG-saporin i.c.v. injections induce selective cholinergic neuron degeneration in the BF.
Reductions of Cerebral Glucose Metabolism after Cholinergic Deafferentation
We used [ 14 C]-2-deoxyglucose in vivo autoradiography to map the effects of cholinergic neuronal and terminal loss on cerebral functional activity, as re- flected by regional glucose utilization. We demonstrate that reductions in glucose metabolism in cortical and hippocampal regions are still evident 18 weeks postlesion using this cholinergic-selective lesion paradigm. While these reductions were statistically significant in four regions at this time-point (hippocampus CA1, CA3, dentate gyrus molecular layer, and parietal cortex layers V-VI, P Ͻ 0.05), the consistent trend toward reduced glucose use in all pre-frontal, frontal and parietal cortex regions examined, and in the amygdala (Ϫ14 -21%), is of added interest. These anatomical subregions correspond to primary NBM cholinergic axonal target zones (35) .
Under normal conditions, dynamic changes in glucose utilization predominantly reflect alterations in energy-consuming events in neuron terminals (39) . The primary glucose use decreases we report are consistent with chronic down-regulation of terminal activity in cholinergic projection zones, putatively due to reduced or impaired neuronal activation. This fact is highlighted by the close correlations between the relatively large reductions in both glucose utilization rates and specific [ 3 H]-vesamicol binding densities (localizing vesicular Ach transporters, and consequently intact cholinergic neuron terminals) evident in BF cholinergic projection target regions (see Tables 1 and 2 ). In contrast, other areas selected as control regions (lacking direct cholinergic innervation from the NBM, e.g., cerebellar grey matter, substantia nigra pars reticulata and compacta, globus pallidus) showed little or no reductions in glucose use in 192-saporin-lesioned rats, compared to levels in nonlesioned control animals. However, glucose use changes induced by neuronal degeneration will also impact on secondary and tertiary projection targets of the denervated region. The magnitude of glucose use changes observed in these "down-stream" constituents of polysynaptic functional pathways might be expected to dissipate sequentially along its components, as the relative contributions of neuronal populations unaffected by the primary insult to the overall regional glucose use rate measured, sequentially increase. This may explain the small magnitude, but nonstatistically significant decreases in glucose use evident in regions that are not innervated directly by BF cholinergic efferents. For example, slight hypometabolism in the striatum may reflect the effects of cholinergic denervation of cortical afferent zones, while striatal hypometabolism may impact functional activity in the substantia nigra via striatofugal projections. In addition, the fact that glucose uptake measurements reflect primarily neuron terminal processes does not rule out the possibility of glucose use changes at the site of insult, in this case the BF nuclei, in response to loss of cell bodies in this region. This is supported by a previous study that showed marked hypermetabolism in the NBM region acutely following excitotoxic injection to this region (9) . In the present study, measurements were made 18 weeks after selective cholinergic cell death, thus the partial reduction in glucose utilization in the NBM likely reflects some loss of cell bodies with concomitant reduced synaptic activity. Hence glucose use changes seen 18 weeks postcholinergic neuronal loss reflect alterations in well organized, functional pathways associated with the basal forebrain cholinergic system. Several previous studies in both rats and baboons used different lesion paradigms to assess glucose utilization after disrupting BF cholinergic projections (9, 37, 44, 47, 60, 61, 80) . However, these investigations were compromised by the lack of a discrete, selective cholinotoxin. Approaches included electrolytic destruction of NBM neurons, excitotoxin injection directly into the NBM region, and BF injections of the cholinotoxin AF64A. The methodological limitations arise because BF cholinergic neurons are widely dispersed among noncholinergic populations. The utility of AF64A is restricted by dose and injection site parameters (30, 71) , while electrolytic techniques lesion not only cell bodies within the target site, but also axons passing through the area. Surgical and excitotoxic lesions of the BF are not sufficiently neuron-specific to produce discrete cholinergic neuronal loss, although recent studies (9, 62, 63) demonstrated that AMPA has greater cholinergic neuron selectivity than other excitotoxins. Furthermore, after unilateral lesioning paradigms, functional recovery may occur due to the influence of the intact contralateral hemispheres.
Previous lesion studies using these approaches reported biphasic effects on cortical glucose utilization. Typically, glucose use was depressed 3-4 days postexcitotoxin-lesion, but recovered to basal levels within 4 weeks after unilateral lesions, and 4 months following bilateral lesions despite sustained ChAT deficits (9, 37, 44, 47, 60, 61, 80) . This functional recovery most likely reflects the lack of cholinergic selectivity of these lesion paradigms, leading to incomplete cholinergic denervation. Of these lesion paradigms, AMPA intra-NBM infection appears to be most potent (9). Browne et al. (9) showed that ipsilateral cortical glucose use depression was sustained up to 24 days after unilateral AMPA injections into the NBM region. In contrast, as shown by our present studies, i.c.v. injections of 192 IgGsaporin directed against the low affinity NGF receptor (p75NGFR) selectively destroy neurons expressing this receptor, principally cholinergic basal forebrain neurons, without concomitant regional tissue or mechanical damage (29, 71) . Furthermore, we demonstrate that both behavioral and cerebral metabolic dysfunction following 192 IgG-saporin injections are still evident 18 weeks postlesion, suggesting that, using this experimental paradigm, the selective cholinergic loss is sufficient to produce sustained metabolic and cognitive deficits more reminicient of the chronic hypometabolism and dementia occurring in AD. This novel obser-vation of a persistent, long-term decrease in glucose use (and therefore in neuronal functional activity) following 192 IgG-saporin i.c.v. injections, differs from the two previous reports of cerebral metabolism measures following cholinotoxic lesioning with 192 IgGsaporin (3, 52) . This reflects the fact that our study employed a bilateral i.c.v. injection paradigm, whereas the previous studies used unilateral lesioning procedures, via unilateral i.c.v. injection (52) or stereotactic NBM lesion (thus only lesioning NBM efferents and sparing hippocampal regions (3)). These studies report a transient increase in glucose use in affected cholinergic projection zones immediately after 192-IgG-saporin injections, which transposed to reduced hippocampal glucose use 30 days after lesion in the i.c.v. injection paradigm (52) . Further, neither study investigated effects on glucose use more than 30 days postlesion. Transient patterns of hypometabolism, as seen following many BF lesion approaches, are not typical of AD. PET studies show that metabolic impairments develop during the early stages of AD, most notably in posterior association (parietotemporal and lateral temporal) and prefrontal cortices. Mild hypometabolism in the parietal association cortex of presymptomatic mutation carriers at risk for familial AD has also been reported (22, 31, 36) . These glucose use deficits in AD patients, which may reflect both local neuronal degeneration and/or synaptic dysfunction due to cholinergic deafferentation, do not recover over time. Therefore, the observation that 192 IgG-saporin lesions induce long lasting glucose use depression in BF projection targets suggest that this lesion technique may be useful in future to assess the efficacies of potential cholinergic therapeutic approaches.
The Cholinergic System and Cognition
Many animal studies have shown that acetylcholine neurotransmission in both neo-and allocortex can, if disrupted, create severe deficits in cognitive function (20, 21) . Deficits in memory tasks have been found after loss of cholinergic input to the hippocampus, based on extensive studies of fimbria-fornix lesions (also creating some extracholinergic damage) (38, 48, 54, 59) or cholinergic degeneration associated with aging (21, 25, 76) . NBM lesions, causing loss of neocortical cholinergic input, have suggested an important role for acetylcholine in cortical neurotransmission for attention to stimuli, and therefore indirectly to learning and memory formation (18, 68, 77) . During aging, a variety of cellular degenerations are associated with cognitive decline and memory dysfunction. This loss of function has been hypothesized to depend, at least in part, on the decline in acetylcholine levels and cholinergic neuronal systems (2, 12, 14, 66, 72) . Cholinergic degeneration is considered to be an important factor underlying memory deficits in neurological disease, such as dementia of Alzheimer's type, and even some Parkinson patients (10, 72, 74, 79) . Severity of dementia, number of plaques and, to some degree, loss of synapses, correlate with the degeneration of the cholinergic system in many Alzheimer's patients (27, 65 ). The precise relationship of the septohippocampal cholinergic system to memory function and symptoms caused by cholinergic neuronal degeneration can be investigated if the model has selective neuronal and terminal loss.
We and others have used the immunotoxic (antibody against NGFr conjugated to saporin) cholinergic lesion model in rodents to assess effects on spatial memory tasks and retention of passive avoidance behavior. After 192-IgG-saporin induced selective cholinergic cell loss in the septo-hippocampal cholinergic system, rats show deficits in acquisition and spatial probe tasks in the Morris swim-maze as well as decreased retention in passive avoidance tests (41, 42) . The immunotoxic rodent model of selective degeneration in the septohippocampal cholinergic system thus supports the role of this system in memory-related functions.
The correlations we have observed in the current study of spatial memory (percent time spent in target quadrant on day 5) with brain glucose metabolism are important for in depth functional analysis. First, because the sustained decrease in cerebral glucose utilization is clearly dependent upon the selective loss of cholinergic input, as demonstrated by our lesion method. Moreover, the fact that performance involving spatial components correlated only in lesioned rats with glucose use in frontal cortex and cholinergic neuron containing nuclei may indicate that the lesioned brain is more dependent and has less distributed function of brain areas during performance of such tasks compared to intact and normal rats (see Table 4 ). This functional analysis suggests that even though the saporin-lesioned rats are defective in their cognitive performance, they are still attempting to solve the task through routes that have previously been demonstrated to be important for spatial memory processing. Some of the behavioral correlations, such as with local cerebral metabolism in the dorsomedial striatum and substantia nigra may not be easily understood from simple anatomical single circuit diagrams. However, much of this spatial and mnemonic processing obviously is going through a number of dependent circuitries and certainly striatum is an important component in subcortical processing, also for cognition (see 17, 33, 78) , and could therefore have some relevance to the overall performance of the lesioned rats. The increased correlation to performance with substantia nigra in the lesioned rats is harder to interpret, but stands as a possible downstream effector region for the many consequences of impaired performance, such as is seen in locomotor hyperactivity of rats with cholinergic deficits or after atropine treatment, and may therefore be ex-plained as a hyperactivity syndrome. Such deficits may also play a role in passive avoidance and in swim maze tests (43) . Nonetheless, the important relative decrease in local glucose utilization and its correlations with specific behavior may be important in understanding of cognitive processing with dysfunctional cholinergic components of the corticohippocampal system.
Cerebral Metabolic Function and APP Processing
Several lines of evidence demonstrate the existence of metabolic defects and increased oxidative stress in AD. Impaired glucose uptake in brain regions exhibiting neuritic plaques occurs in AD patients (34) , and deficits in cerebral glucose utilization may occur early in the process of the disease, preceding neuronal degeneration (36) . Decreased activity of mitochondrial metabolic enzymes, including dehydrogenases and cytochrome c oxidase has been reported in AD brain (6) , while glucose uptake transporters are also down-regulated (73) . Of importance, recent evidence suggests a mechanistic link between disturbed energy metabolism and altered APP processing. Inhibiting mitochondrial energy metabolism with sodium azide leads to markedly enhanced amyloidogenic processing of APP in cell lines (24) . Furthermore, Gasparini et al. (26) reported that both glucose deprivation and inhibiting energy metabolism with sodium azide reduced APPs secretion, while treatment with the antioxidant glutathione fully reversed azide's inhibitory effect. Hypoglycemia elevates the expression of APP mRNA in astroglial cells, and leads to enhanced alternative APP splicing that encodes a kunitz-type serine protease inhibitor domain, which has been shown to partially counteract the A␤ degradation (55) . Also, Copani et al. (13) observed enhanced A␤ toxicity in mouse cortical neuronal culture following energy failure after glucose deprivation. APPs is postulated to be protective against excitotoxic, metabolic, and oxidative insults (51) , and thus reduced levels of APPs due to metabolic dysfunction may be detrimental to neurons. Taken with our previous finding of elevated APP levels in the animal model used in this study (45, 46) , these observations suggests that impaired energy metabolism may contribute to the pathogenesis of AD by altering APP processing, leading to reduced APP secretion and increased amyloidogenic derivatives. As a consequence, altered APP processing may in turn disrupt energy metabolic function further. Interestingly, this hypothesis is further supported by findings that transgenic mice overexpressing human APP exhibit reductions in cerebral glucose metabolism (32) . In addition, human APP expression in hippocampal and cortical neurons impairs glucose transport and suppresses ATP production by a mechanism involving membrane lipid peroxidation (49) . Overall, the results reported in this study strengthen the argument that APP processing and energy metabolism in the brain are functionally related, and modulation of APP processing resulting from impaired energy metabolism could play a significant role in the pathogenesis of AD.
